Evidence map›Paper›PMID 31320999›Full record

ArticleOncotarget2019

CD90

Yang Zeng, Binghao Li, Tao Li, Wei Liu, Chongzhao Ran, Richard T Penson, Mark C Poznansky, Yanan Du, Huabiao Chen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Yang ZengVaccine and Immunotherapy Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
Binghao LiVaccine and Immunotherapy Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
Tao LiVaccine and Immunotherapy Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
Wei LiuDepartment of Biomedical Engineering, School of Medicine, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Tsinghua University, Beijing 100084, China.
Chongzhao RanMartinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown 02129, USA.
Richard T PensonMedical Gynecologic Oncology, Gillette Center for Women's Cancers, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
Mark C PoznanskyVaccine and Immunotherapy Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
Yanan DuDepartment of Biomedical Engineering, School of Medicine, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Tsinghua University, Beijing 100084, China.
Huabiao ChenVaccine and Immunotherapy Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
Massachusetts General Hospital · USHarvard University · USTsinghua University · CNAthinoula A. Martinos Center for Biomedical Imaging · USDana-Farber Cancer Institute · US

Funding

Influx Flow CytometerS10OD016372 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI PREFFER, FREDERIC IRA · 2013 to 2013
$600k
ImageStream X Analyzer 2011S10OD012027 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI PREFFER, FREDERIC IRA · 2012 to 2012
$595k
Translational Immunology Core's FACSAria Cell SorterS10RR023440 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI PREFFER, FREDERIC IRA · 2008 to 2008
$500k
DEPARTMENT OF PATHOLOGY LSR2 CYTOMETER: TRANSPLANTATIONS10RR020936 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI PREFFER, FREDERIC IRA · 2005 to 2005
$389k
NCRR NIH HHS S10 RR020936NCRR NIH HHS S10 RR023440NIH HHS S10 OD012027NIH HHS S10 OD016372
6 · The paper itself

Abstract

Both anti-tumoral and pro-tumoral effects of mesenchymal stem cells (MSCs) in preclinical treatment of ovarian cancer have been controversially demonstrated. In this study, we profiled the phenotypes of mouse compact bone-derived MSCs (CB-MSCs) and bone marrow-derived MSCs (BM-MSCs) and found that CB-MSCs expressed lower CD90 compared to BM-MSCs. We examined gene expression of immune regulating cytokines of CB-MSCs in 2D and 3D culture and under stimulation with TLR4 agonist LPS or immune activator VIC-008. Our data showed that when CB-MSCs were cultured in simulated

Indexed as

CD90immunotherapymesenchymal stem cellsovarian cancer

Identifiers

PMID31320999
PMCPMC6633895
OpenAlexW2980731407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.